Ovarian Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797411
  • Drug Pipelines
  • 239 pages
  • Datamonitor Healthcare
1 of 3
The ovarian cancer market is poised for growth, which will be driven by increasing incidence of the disease, newly approved therapies, and Lynparza’s label expansions.

This report addresses the following questions:

- What is the overall market potential for Lynparza in ovarian cancer patients?
- What impact will bevacizumab biosimilars have on Avastin’s market share after the expiration of its key patents?
- How will PARP inhibitors rucaparib and niraparib compete against Lynparza in BRCA-mutated patients?
- Which pipeline drugs will seek to address the unmet need of treating platinum-resistant advanced ovarian cancer patients?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: OVARIAN CANCER

- Executive Summary
- Market Overview and Trends
- Methodology and Market Definition
- Avastin (bevacizumab)
- Lynparza (olaparib)
- Niraparib
- Perjeta (pertuzumab)
- Recentin (cediranib)
- Rucaparib
- Vigil (FANG vaccine)
- Primary Research Methodology

TREATMENT: OVARIAN CANCER

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Current Treatment Options
- Unmet Needs in Ovarian Cancer

EPIDEMIOLOGY: OVARIAN CANCER IN THE US, JAPAN, AND 5EU

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: OVARIAN CANCER

- Executive Summary
- Product Overview
- Product profile: Avastin
- Product profile: Lynparza

PIPELINE: OVARIAN CANCER

- Executive Summary
- Clinical Pipeline Overview
- Early-Phase Opportunities
- Recently Discontinued Drugs
- Target Product Profile
- Product profile (late stage): Perjeta
- Product profile (late stage): Recentin
- Product profile (late stage): Vigil
- Product profile (late stage): binimetinib
, 36.Product profile (late stage): niraparib
- Product profile (late stage): rucaparib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll